ETC’s Commercial/Industrial Unit Awarded Contracts Totaling $9.1 Million 7-11-2025, 21:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Pacific Green and SSE enter into Energy Optimization Agreement for Pacific Green’s 249MW / 373.5MWh Sheaf Energy Park Battery Development 21-11-2023, 20:00